Episode Details
Back to Episodes
FDA Approves Breakthrough Pancreatic Cancer Drug | Health and Fitness News
Description
FDA just approved daraxonrasib (RASONQUE) — the first drug to directly target a stubborn KRAS mutation in advanced pancreatic cancer. Patients on this new therapy lived twice as long compared to standard chemo, marking a historic leap forward after decades of failed attempts. This breakthrough underscores the power of clinical trials and patient courage, offering renewed hope for one of medicine’s toughest battles.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/9d1b090724b5acc5